NV1020* is currently developed as an oncolytic virus. It is a herpes simplex virus, genetically modified for the specific destruction of tumor cells without harming healthy tissue.
The forthcoming trial will evaluate the safety, tolerability and efficacy of NV1020*, as well as its synergies with chemotherapy. It will include about 30 patients in up to 7 clinical centers in the United States.
The positive results obtained in a clinical phase 1 trial of NV1020* form the basis for this trial and MediGene expect the results of the phase 1/2 study by mid 2006.
Dr Peter Heinrich comments, "Cancer-killing viruses like NV1020* are among the most innovative products of today's drug development".
"If the development of NV1020* proceeds as successfully in the future as it has up to now, MediGene may become the first company wordwide to develop a virus mutant cancer drug to market maturity."
"This could be a very valuable contribution to improvement in cancer therapy."
* temporary name while under development.